Biotech will continue to deliver 'double-digit growth' - Daniel Koller

BB Biotech's Head of Investment, Daniel Koller, explains why the sector's fundamentals are all lined up to the upside.

Partner insight Regulatory approvals of biotech drugs, ongoing takeover activity, and successful clinical trials involving new treatment approaches are three reasons why savvy investors should be looking at biotech, according to Daniel Koller. Speaking to Investment Week, the manager of the BB Biotech AG trust said advances in biology and science are creating tangible benefits for patients and there are lots of opportunities to do in-depth, fundamental analysis on product launch trends and clinical data events. And M&A is bouncing back. Big Pharma has over $500 billion in cash to depl...